Palliative Care • October 14, 2026
Palliative Care Innovation: Psilocybin for End-of-Life Cancer Anxiety and Existential Distress
Over 80% of life-threatening cancer patients receiving psilocybin reported sustained decreases in existential anxiety and death-related distress at 6-month follow-up.
The Burden of Existential Distress in Terminal Diagnosis
Patients diagnosed with terminal cancer frequently experience profound demoralization, existential dread, and severe anxiety that conventional palliative medication fails to resolve.
Johns Hopkins & NYU Landmark Double-Blind Studies
In landmark trials led by Johns Hopkins University and NYU, high-dose psilocybin session combined with non-directive psychotherapy produced immediate, significant decreases in clinician-rated anxiety and depression scales.
Six-Month Sustained Shifts in Meaning and Well-Being
At the 6-month follow-up, 80% of participants continued to show clinically meaningful reductions in depression and anxiety, reporting increased quality of life, spiritual well-being, and peace regarding mortality.